Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lisata Therapeutics, Inc. - Common Stock
(NQ:
LSTA
)
1.550
+0.430 (+38.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lisata Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
↗
January 22, 2025
Via
Benzinga
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
January 15, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
December 10, 2024
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal cancers
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Earnings Outlook For Lisata Therapeutics
↗
November 11, 2024
Via
Benzinga
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
December 03, 2024
License provides Lisata’s innovative certepetide targeting agent for use with Kuva’s NanoMark™ MR imaging platform to advance non-invasive, high-precision cancer diagnostics
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
November 19, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Dave Mazzo, CEO of Lisata Therapeutics Inc. (NASDAQ: LSTA), to Present at NobleCon20
November 12, 2024
Via
Investor Brand Network
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
November 06, 2024
Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
November 06, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
October 31, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
October 28, 2024
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
October 03, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
September 17, 2024
Study arm initiated based upon enthusiasm and at the request of investigators who participated in first-line cholangiocarcinoma cohort
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
September 09, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
September 05, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024
↗
August 12, 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
August 05, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
July 18, 2024
From
Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via
GlobeNewswire
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
↗
July 18, 2024
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing...
Via
Benzinga
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
July 16, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
July 10, 2024
Certepetide shown to promote immune cell infiltration into tumors and inhibit metastasis
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
June 13, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
May 28, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
May 20, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
May 13, 2024
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Via
News Direct
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
May 13, 2024
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo tells Proactive's Stephen Gunnion that 2024 is a pivotal year for the oncology company, with Phase 2b ASCEND trial top-line data expected in the...
Via
TheNewswire.com
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q1 2024
↗
May 09, 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
